| PDI Healthcare is testing several of its disinfectant products for efficacy against SARS-CoV-2, the virus that causes COVID-19, for submission to the EPA for approval. Partnering with Microbac Laboratories, Inc. for testing, PDI hospital-grade products could become among the products with demonstrated effectiveness against the novel coronavirus. Infection prevention experts have been looking to the EPA’s Emerging Viral Pathogens Program for guidance on what products may work as disinfectants. The program is intended to bridge the gap when outbreaks occur, giving laboratories time to acquire the novel virus for product testing. |
Connect - Convene - Collaborate